← All candidates
63 insider filings on record.
63 filings on record.
RCUSArcus Biosciences, Inc.
NYSE · Healthcare · $3.10B
$24.65
+1.36% · Sep 16
63 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 41 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.10B
Float
90.5M
72% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
26.5
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
58 more transactions on Pro →Context
Wall St
$35.75 avg target
+45.0% vs today · 12 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$1.02 act−$0.19
Q4 '25−$0.89 act+$0.18
Q3 '25−$1.27 act+$0.02
Q2 '25$0.00 act+$1.17
Coverage
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer CombinationInsider Monkey · 07-01Arcus, Bristol Myers Team Up to Advance Kidney Cancer StudyZacks · 06-04Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue ForecastsSimply Wall St. · 05-16Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter ReportSimply Wall St. · 05-08
The file stays open
63 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice